Evaluation of cis-platinum and DTIC combination chemotherapy in disseminated melanoma. A Southwest Oncology Group Study.
Evaluation of cis-platinum and DTIC combination chemotherapy in disseminated melanoma. A Southwest Oncology Group Study.
复制标题
顺铂和 DTIC 联合化疗治疗播散性黑色素瘤的评价。
DOI：
10.1097/00000421-198810000-00016
复制
发表时间：
1988
期刊：
影响因子：
--
通讯作者：
Townsend,RA
中科院分区：
文献类型：
--
作者：
Fletcher,WS;Green,S;Fletcher,JR;Dana,B;Jewell,W;Townsend,RA
播散性黑色素瘤的发展与预后极差有关。单独或联合使用多种化疗药物的有效率仅为10-30%。手术和放射治疗在姑息治疗中发挥了有益的作用，但在治疗播散性疾病中很少或没有价值。为了评估播散性恶性黑色素瘤对顺铂和5-（3,3 -二甲基-1-三氮杂化）咪唑-4-羧酰胺（DTIC）联合化疗的反应，俄勒冈健康科学大学开展了一项II期试点研究。从1983年1月至1986年10月对30例患者进行了治疗和评估。有2例完全缓解（7%）和9例部分缓解（30%），总缓解率为37%。中位反应持续时间为31周。这一缓解率高于先前使用DTIC和顺式铂，或单独或联合使用其他药物所达到的缓解率。30例患者中分别有4例、3例和10例出现严重（3级）肾、神经和血液毒性。
The development of disseminated melanoma is associated with an extremely poor prognosis. Use of a variety of chemotherapy agents alone and in combination has yielded response rates of only 10–30%. Surgery and radiation therapy play a useful role in palliative treatment, but have little or no value in the treatment of disseminated disease. In order to evaluate the response of disseminated malignant melanoma to combination chemotherapy with cis-platinum and 5-(3, 3-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC), a phase II pilot study was developed and conducted at Oregon Health Sciences University. Thirty patients were treated from January 1983 to October 1986 and evaluated. There were two complete responses (7%) and nine partial responses (30%) for a total response rate of 37%. The median duration of response was 31 weeks. This response rate is higher than has been previously achieved with DTIC and cis-platinum, or with other drugs alone or in combination. Severe (grade 3) renal, neurologic, and hematologic toxicity was seen in four of 30, three of 30, and ten of 30 patients, respectively.